MA27904A1 - Forme dosifiee orale de mesylate de saquinavir - Google Patents
Forme dosifiee orale de mesylate de saquinavirInfo
- Publication number
- MA27904A1 MA27904A1 MA28709A MA28709A MA27904A1 MA 27904 A1 MA27904 A1 MA 27904A1 MA 28709 A MA28709 A MA 28709A MA 28709 A MA28709 A MA 28709A MA 27904 A1 MA27904 A1 MA 27904A1
- Authority
- MA
- Morocco
- Prior art keywords
- mesylate
- saquinavir
- saquinavir mesylate
- disintegrant
- solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne une forme dosifiée pharmaceutique orale formant une unité solide de mésylate de saquinavir comprenant du mésylate de saquinavir microlysé, dans une quantité comprise entre 250 mg et 800 mg, calculée en tant que base libre, et un liant pharmaceutiquement acceptable, un désintégrant, un vecteur soluble dans l'eau. L'invention concerne une forme dosifiée formant une unité solide de mésylate de saquinavir comprenant entre 60 % et 80 % de mésylate de saquinavir microlysé, à base de sel de mésylate, de 4 à 8 % d'un liant soluble dans l'eau, un désintégrant et un vecteur, chaque pourcentage est calculé par rapport au poids de noyau.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48660003P | 2003-07-11 | 2003-07-11 | |
US56820404P | 2004-05-05 | 2004-05-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27904A1 true MA27904A1 (fr) | 2006-05-02 |
Family
ID=34068244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28709A MA27904A1 (fr) | 2003-07-11 | 2006-01-06 | Forme dosifiee orale de mesylate de saquinavir |
Country Status (24)
Country | Link |
---|---|
US (2) | US20050009811A1 (fr) |
EP (1) | EP1646369B1 (fr) |
JP (2) | JP4608488B2 (fr) |
KR (2) | KR100767271B1 (fr) |
AU (1) | AU2004255436B2 (fr) |
BR (1) | BRPI0412523A (fr) |
CA (1) | CA2531486C (fr) |
CO (1) | CO5640069A2 (fr) |
CR (1) | CR8172A (fr) |
EA (1) | EA015349B1 (fr) |
EC (1) | ECSP066274A (fr) |
HK (1) | HK1089959A1 (fr) |
IL (1) | IL172890A (fr) |
MA (1) | MA27904A1 (fr) |
MX (1) | MXPA06000363A (fr) |
MY (1) | MY140413A (fr) |
NO (1) | NO20060313L (fr) |
NZ (1) | NZ544585A (fr) |
PA (1) | PA8606001A1 (fr) |
PE (1) | PE20050247A1 (fr) |
RS (1) | RS20060009A (fr) |
TN (1) | TNSN06003A1 (fr) |
TW (1) | TWI356711B (fr) |
WO (1) | WO2005004836A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001034119A2 (fr) | 1999-11-12 | 2001-05-17 | Abbott Laboratories | Inhibiteurs de cristallisation dans une dispersion solide |
JP4608488B2 (ja) * | 2003-07-11 | 2011-01-12 | エフ.ホフマン−ラ ロシュ アーゲー | メシル酸サキナビル経口投与剤型 |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
EP2168573A1 (fr) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations contentant d'ézétimibe |
WO2013172297A1 (fr) | 2012-05-14 | 2013-11-21 | 塩野義製薬株式会社 | Préparation contenant un dérivé de 7-carbamoylmorphinane 6,7-insaturé |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
JP2642486B2 (ja) * | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | 難溶性薬物の超微粒子化法 |
GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
CA2124568C (fr) * | 1992-10-09 | 2003-11-11 | Yoshiaki Yano | Procede de production de microgranules |
TW390813B (en) * | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5608085A (en) * | 1995-02-27 | 1997-03-04 | The University Of Tennessee Research Corporation | Synthesis of optically active calanolides A and B and enantiomers and related compounds |
US6177460B1 (en) * | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
US6514530B2 (en) * | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
CN1148169C (zh) * | 1998-04-09 | 2004-05-05 | 弗·哈夫曼-拉罗切有限公司 | 通过溶于压缩气体和表面活性剂制备(亚)微米级粒子的方法 |
AU765909C (en) * | 1998-12-17 | 2004-09-23 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
EP1247456A3 (fr) * | 2001-02-28 | 2003-12-10 | Pfizer Products Inc. | Compositions pharmaceutiques savoureux pour les animaux domestiques |
US20030068356A1 (en) * | 2001-07-10 | 2003-04-10 | Pather S. Indiran | Sequential drug delivery systems |
JP4608488B2 (ja) * | 2003-07-11 | 2011-01-12 | エフ.ホフマン−ラ ロシュ アーゲー | メシル酸サキナビル経口投与剤型 |
-
2004
- 2004-07-05 JP JP2006519808A patent/JP4608488B2/ja not_active Expired - Lifetime
- 2004-07-05 EA EA200600156A patent/EA015349B1/ru not_active IP Right Cessation
- 2004-07-05 KR KR1020067000732A patent/KR100767271B1/ko active IP Right Grant
- 2004-07-05 AU AU2004255436A patent/AU2004255436B2/en not_active Ceased
- 2004-07-05 NZ NZ544585A patent/NZ544585A/en not_active IP Right Cessation
- 2004-07-05 RS YUP-2006/0009A patent/RS20060009A/sr unknown
- 2004-07-05 BR BRPI0412523-1A patent/BRPI0412523A/pt not_active IP Right Cessation
- 2004-07-05 EP EP04763093.4A patent/EP1646369B1/fr not_active Expired - Lifetime
- 2004-07-05 MX MXPA06000363A patent/MXPA06000363A/es active IP Right Grant
- 2004-07-05 WO PCT/EP2004/007309 patent/WO2005004836A2/fr active IP Right Grant
- 2004-07-05 CA CA2531486A patent/CA2531486C/fr not_active Expired - Lifetime
- 2004-07-05 KR KR1020077016817A patent/KR20070087194A/ko not_active Application Discontinuation
- 2004-07-07 PE PE2004000651A patent/PE20050247A1/es not_active Application Discontinuation
- 2004-07-07 TW TW093120382A patent/TWI356711B/zh not_active IP Right Cessation
- 2004-07-07 PA PA20048606001A patent/PA8606001A1/es unknown
- 2004-07-08 US US10/886,765 patent/US20050009811A1/en not_active Abandoned
- 2004-07-09 MY MYPI20042754A patent/MY140413A/en unknown
-
2005
- 2005-12-29 IL IL172890A patent/IL172890A/en not_active IP Right Cessation
-
2006
- 2006-01-05 CR CR8172A patent/CR8172A/es unknown
- 2006-01-06 MA MA28709A patent/MA27904A1/fr unknown
- 2006-01-06 CO CO06001295A patent/CO5640069A2/es not_active Application Discontinuation
- 2006-01-06 TN TNP2006000003A patent/TNSN06003A1/en unknown
- 2006-01-09 EC EC2006006274A patent/ECSP066274A/es unknown
- 2006-01-20 NO NO20060313A patent/NO20060313L/no not_active Application Discontinuation
- 2006-09-25 HK HK06110649.8A patent/HK1089959A1/xx not_active IP Right Cessation
-
2008
- 2008-10-31 US US12/262,607 patent/US20090054481A1/en not_active Abandoned
-
2010
- 2010-08-13 JP JP2010181350A patent/JP2010280707A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27904A1 (fr) | Forme dosifiee orale de mesylate de saquinavir | |
MA26629A1 (fr) | Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production | |
TNSN01123A1 (fr) | Formes posologiques nouvelles a liberation controlee | |
MA24930A1 (fr) | Forme posologique a usage oral comprenant une combinaison de metformine et de glibenclamide | |
EA200401009A1 (ru) | Предварительно желатинированный крахмал в композиции с контролируемым высвобождением | |
MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
MA27729A1 (fr) | Compositions pharmaceutiques solides contenant un agoniste des recepteurs de la s1p et un alcool de sucre | |
EE9800050A (et) | Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine | |
EP1982713A3 (fr) | Benzoxazoles substitués et analogues utilisés en tant qu'agents oestrogènes pour le traitement des maladies intestinales inflammatoires | |
CA2330500A1 (fr) | Compositions pharmaceutiques gelifiables | |
HK1087336A1 (en) | Pharmaceutical composition comprising lumiracoxib | |
EA200000246A1 (ru) | Быстро дезинтегрирующие таблетки метилцеллюлозы | |
HK1076382A1 (en) | Process for preparing a finely self-emulsifiable pharmaceutical composition | |
HUP0101411A2 (hu) | 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása | |
MA29451B1 (fr) | Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme | |
MA27123A1 (fr) | Forme solide d'administration d'acide diphosphonique ou de sel de celui-ci, utilisant l'acide stearique comme lubrifiant, et procede pour la preparer | |
WO2001092283A3 (fr) | Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie | |
HUP0103454A2 (hu) | Entacapont vagy nitecapont és keresztkötésű cellulózszármazékot tartalmazó gyógyászati készítmény | |
MA27772A1 (fr) | Preparation pharmaceutique orale destinee aux antagonistes de la pompe a protons | |
FR2784899B1 (fr) | Agoniste, agoniste partiel ou antagoniste du recepteur 5-ht4 ou un sel pharmaceutiquement acceptable de ceux-ci pour utilisation dans la fabrication d'une composition pharmaceutique, y compris a usage veterinaire | |
CA2503211A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire | |
WO1999047172A3 (fr) | Compositions pharmaceutiques orales a prendre sans liquides et contenant des composes d'inclusion | |
AP2001002119A0 (en) | Sertraline oral concentrate. | |
MA27864A1 (fr) | Composition pharmaceutique pour l'administration par voie nasale de piribedil | |
MA31541B1 (fr) | Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine |